权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cancer Immunology (CI) (Project-001)

癌症免疫学 (CI)（项目-001）

基本信息

批准号：
8932191
负责人：
Nina Bhardwaj
金额：
$ 0.93万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-08-01 至 2020-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8932191
关键词：
Adjuvant Affect Antigen Presentation Antigen-Presenting Cells Award Biology Cancer Center Support Grant Cancer Immunology Science Cells Cellular biology Clinical Clinical Trials Cytotoxic T-Lymphocytes Dendritic Cell Vaccine Dendritic Cells Development Doctor of Philosophy Environment Genomics Goals Grant Helper-Inducer T-Lymphocyte Immune Immune System Diseases Immune response Immune system Immunologic Monitoring Immunologist Immunology Immunosuppression Immunotherapy Inflammatory Response Institutes Joints Journals Lead Malignant Neoplasms Mediating Outcome Peer Review Pre-Clinical Model Publications Publishing Reporting Research Research Personnel Role T-Lymphocyte Testing Tissues Translating Tumor Antigens Tumor Immunity abstracting base cancer immunotherapy immunogenicity improved inhibitor/antagonist macrophage member novel pre-clinical programs tumor tumor growth tumor microenvironment tumor progression

项目摘要

ABSTRACT – CANCER IMMUNOLOGY RESEARCH PROGRAM Program Leaders: Nina Bhardwaj, MD, PhD Miriam Merad, MD, PhD Cancer progression is characterized by gradual dysregulation of the immune system at multiple levels that is considered to directly contribute to unchecked tumor growth. The central theme of the Cancer Immunology (CI) Research Program is to identify mechanisms underlying the suppression of effective anti-tumor immunity that could instruct the development of novel and impactful immunotherapies. Dendritic cells (DCs), potent antigen presenting cells, initiate anti-tumor immune responses, which are subsequently mediated by CD4+ helper cells and cytotoxic T cells. Immunologists have historically focused on characterizing the role of tumor infiltrating T cells (TILs) in restraining tumor growth, but there is emerging evidence that innate immune cells, such as DC and macrophages, are strongly affected by the tumor micro-environment (TME) and major contributors to tumor progression. The CI Research Program has three main scientific objectives. They are to: 1) Characterize mechanisms underlying DC and macrophage immune dysregulation in the tumor micro-environment; 2) Develop preclinical models to reverse innate immune dysfunction and restore immunogenicity to tumor associated antigens, and 3) Translate preclinical discoveries into cancer immunotherapy trials. The CI program has 21 members, and they represent 10 departments and 3 institutes (The Tisch Cancer Institute, Immunology Institute, Icahn Institute for Genomics and Multiscale Biology). As of July 1, 2014, program members were awarded $4,016,010 in NCI and other peer reviewed cancer-related direct support. Members of the CI Program have been increasingly successful in publishing their research in high impact journals. Since 2011, CI program members published 163 reports, of which 14.7% were intra-programmatic and 23.9% inter-programmatic.

摘要-癌症免疫学研究计划